Serum and bone concentrations of teicoplanin and vancomycin: Study in an animal model

Drugs under Experimental and Clinical Research

Volumn 24, Issue 4, 1998, Pages 185-190

  Drago, L ^a,b   De Vecchi, E ^a   Fassina, M C ^a   Gismondo, M R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Laboratory of Microbiology LITA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BONE AND JOINT INFECTIONS; BONE LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORTHOPEDIC SURGERY;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BONE AND BONES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; FEMALE; GUINEA PIGS; HALF-LIFE; INJECTIONS, INTRAVENOUS; TEICOPLANIN; VANCOMYCIN;

EID: 0032466082     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Weinberg W.G. Safety and efficacy of teicoplanin for bone and joint infections: results of a community-based trial. South Med. J., 86, 891, 1993.
2. Parenti F. Structure and mechanism of action of teicoplanin. J. Hosp. Infect., 7 (Suppl. A), 79, 1986.
3. Somma S., Gastaldo L., Corti A. Teicoplanin, a new antibiotic from Actynoplanes teichomycetus nov. sp. Antimicrob. Agents Chemothee, 26, 917, 1984.
4. De Lalla F., Tramarin A. A risk benefit assessment of teicoplanin in the treatment of infections. Drug Safety, 13, 317, 1995.
5. Rowland M. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet., 18, 184, 1990.
6. Lode H., Boeckh M., Hoffken G., et al. Comparative pharmacokinetics of glycopeptide antibiotics, and the influence of teicoplanin on granulocyte function. Scand. J. Infect. Dis., 72 (Suppl.), 9, 1990.
7. Dykhuizen R.S., Harvey G., Stephenson N., Nathwani D., Gould I.M. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob. Agents Chemother, 39, 1842, 1995.
8. Gorbach S.L., Condon R.E., Conte J.E., Kaiser A.B., Ledger W.J., Nichols R.L. Evaluation of new antiinfective drugs for surgical prophylaxis. Clin. Infect. Dis., 15, S313, 1992.
9. Wilson K.J., Mader J.T. Concentrations of vancomycin in bone and serum of normal rabbits and those with osteomyelitis. Antimicrob. Agents Chemother, 25, 140, 1984.
10. Graziani A.L., Lawson L.A., Gibson G.A., Steimberg M.A., MacGregor R.R. Vancomycin concentrations in infected and noninfected human bone. Antimicrob. Agents Chemother, 32, 1320, 1988.
11. LeFrock J.L., Ristuccia A.M., Ristuccia P.A., et al. Teicoplanin in the treatment of bone and Joint infection. Acta Chir., S567, 9, 1992.
12. De Lalla F., Novelli A., Pellizer G., et al. Regional and systemic prophylaxis with teicoplanin in monolateral and bilateral total knee replacement procedures: study of pharmacokinetics and tissue penetration. Antimicrob. Agents Chemother, 37, 2693, 1993.
13. Jehl F., Monteil H., Tarral A. HPLC quantification of the six main components of teicoplanin in biological fluids. J. Antimicrob. Chemother, 21 (Suppl. A), 53, 1988.
14. McMullin C.M., White L.O., MacGowan A.P., Holt H.A., Lovering A.M., Reeves D.S. Assay of serum teicoplanin concentration in clinical specimens: a comparison of isocratic high performance liquid chromatography with polarization fluoroimmune assay and bioassay. J. Antimicrob. Chemother, 34, 425, 1994.